GlassScriptPhysician profile
Jessica J Mccool
NPI 1053600296
$3,137.20
in general payments reported to CMS, 2019-2025
36 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $202 · 2021: $11.45 · 2022: $123 · 2023: $360 · 2024: $592 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.88 | 2019-2025 | Xifaxan |
| Abbvie INC. | $326.60 | 2022-2025 | |
| Pfizer INC. | $320.77 | 2019-2025 | |
| Novo Nordisk INC | $306.28 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $265.13 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $183.04 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $173.48 | 2019-2025 | Evenity, Prolia, Prolia |
| Supernus Pharmaceuticals, INC. | $121.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $116.26 | 2019 | |
| Astellas Pharma US INC | $102.31 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $90.48 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.02 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $72.04 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $66.16 | 2019-2020 | |
| Stryker Corporation | $47.44 | 2025 | Variax, Fixos, Augment Injectable |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.60 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $39.97 | 2023 | Rexulti |
| Medtronic, INC. | $36.62 | 2023 | Ligasure |
| Allergan, INC. | $35.04 | 2019-2020 | |
| Boston Scientific Corporation | $34.06 | 2019-2023 | |
| Verona Pharma, INC. | $31.00 | 2025 | Ohtuvayre |
| Scpharmaceuticals INC. | $27.97 | 2024 | |
| Abbott Laboratories | $27.88 | 2023 | Freestyle Libre 3 |
| Jazz Pharmaceuticals INC. | $27.69 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.05 | 2019-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.70 | 2019-2025 | |
| Mylan Specialty L.P. | $25.94 | 2019 | |
| Lundbeck LLC | $23.27 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $22.88 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.25 | 2025 | |
| Acadia Pharmaceuticals INC | $14.83 | 2020 | |
| Exact Sciences Corporation | $13.65 | 2025 | Cologuard Collection Kit |
| Dermira, INC. | $13.03 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.30 | 2022 | |
| Genentech USA, INC. | $11.09 | 2019 | |
| Therapeuticsmd, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mccool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.